Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 480 | 42% |
| 2020 | 12 | 427 | 45% |
| 2021 | 9 | 346 | 48% |
| 2022 | 8 | 381 | 51% |
| 2023 | 11 | 369 | 54% |
| 2024 | 6 | 353 | 56% |
| 2025 from claims | – | 352 285–413 | 57% |
| 2026 forecast | – | 358 280–449 | 57% |
| 2027 forecast | – | 362 268–479 | 58% |
| 2028 forecast | – | 366 259–506 | 58% |
| 2029 forecast | – | 371 252–532 | 59% |
| 2030 forecast | – | 375 246–557 | 60% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nevada; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 5% hospital outpatient, 95% surgery center. The share outside the hospital has moved +23 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~360 | ~12 | ~350 |
| 2027 · ~360 | ~10 | ~350 |
| 2028 · ~370 | ~9 | ~360 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 98% (95% in 2025), hospital outpatient about 2% (5% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 48 | 1,564−4.8%/yr | −4.8%/yr | 0.4 | 89% | 1,890 in 2030+3.2%/yr |
| Arizona | 28 | 930+0.9%/yr | +0.9%/yr | 1.2 | 78% | 1,060 in 2030+2.2%/yr |
| Utah | 9 | 400+6.6%/yr | +6.6%/yr | 1.7 | 75% | 450 in 2030+2.2%/yr |
| Washington | 15 | 398−5.8%/yr | −5.8%/yr | 0.5 | 76% | 450 in 2030+2.1%/yr |
| Oregon | 11 | 336−6%/yr | −6%/yr | 0.7 | 95% | 480 in 2030+6.2%/yr |
| Colorado | 6 | 257−4.5%/yr | −4.5%/yr | 0.5 | 65% | 390 in 2030+7.1%/yr |
| Idaho | 7 | 175−2.7%/yr | −2.7%/yr | 0.8 | 46% | 200 in 2030+1.9%/yr |
| Montana | 3 | 110−6%/yr | −6%/yr | 0.6 | 17% | 90 in 2030−3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 54 | 3,899−4.7%/yr | −4.7%/yr | 12.91.3× | 98% | 4,350 in 2030+1.8%/yr |
| Peripheral nerve stimulation & intrathecal pumps | 2 | 316−0.6%/yr | −0.6%/yr | 1.01.1× | 71% | 550 in 2030+9.6%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
Abbott leads with 30% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 8 companies reported engagement with Nevada’s surgeons worth $254K in consulting, speaking, meals and travel tied to these products, about $42K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.